Creatine kinase and blood pressure response

Withdrawn

• Conditions: high blood pressure; Hypertension; 10057166

• Registration Number: NL-OMON37003
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Ambulatory adult subjects age 18-60 years, with newly detected hypertension stage I and II in primary care (SBP/DBP * 140/90 and SBP/DBP < 180/110 on at least two consecutive visits), after drie days of rest, otherwise healthy, without clinical or laboratory evidence of muscle damage.

Exclusion Criteria

No rest during the last 3 days, treated hypertension, severe (SBP * 180 mm Hg) hypertension, secondary hypertension, (history of) cardiovascular disease including TIA and stroke, myocardial infarction, angina, BMI>/= 30 kg/m2, diabetes mellitus, lipid spectrum abnormalities, thyroid, kidney, or liver abnormalities; CK-increasing drugs including statins; neuromuscular or endocrine disorders; vasculitis; HIV infection; infectious hepatitis.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The difference in blood pressure response after 3 weeks of treatment in<br /><br>relation to baseline serum CK. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The difference between serum CK activity at baseline and after 3 weeks of<br /><br>treatment with antihypertensive drugs. </p><br>